Gilead opting against IDE397 is still good news for Ideaya.
ApexOnco Front Page
Recent articles
Progression-free and overall survival data from Companion-002 are due this quarter.
AstraZeneca bags three of the month’s four oncology approvals.
Keenly awaited trials of ficerafusp alfa, Trodelvy and divarasib materialise.
Firce-1 is scrapped after showing dismal response rates and patient deaths.
Meanwhile, Olema’s KAT6 inhibitor will take on rival projects from Pfizer and Menarini.
On a wing and a prayer Leap heads for phase 3.
But the new focus on a predictive biomarker could cut the market in half.
